Many patients with type 1 diabetes (T1D) struggle to achieve glycaemic control and experience significant fluctuations in glucose concentrations, despite insulin treatment.
| INTRODUCTION
Individuals with type 1 diabetes (T1D) comprise approximately 5% to 10% of the overall population with diabetes, while those with type 2 diabetes (T2D) comprise the majority. Accordingly, most research efforts aimed at developing new glucose-lowering treatments have focused on T2D, leading to the approval of multiple classes of glucose-lowering agents. In contrast, insulin analogues and the amylin analogue pramlintide, which is infrequently used, remain essentially the only treatment options available for T1D in the United States.
Insulin therapy is designed to mimic endogenous insulin secretion patterns and has been the mainstay for patients with T1D. However, a basal-bolus regimen cannot perfectly mimic endogenous insulin secretion, and while exogenous insulin is essential for preventing excessively high blood glucose concentrations, insulin-treated patients often oscillate between hyperglycaemia and hypoglycaemia. Intensive treatment with insulin titrated to provide tight control of glycated haemoglobin (A1C) was shown to lower the risk of long-term microvascular and macrovascular complications in the Diabetes Control and Complications Trial; yet, overtreatment with insulin poses an increased risk of hypoglycaemia. [1] [2] [3] Data from the T1D Exchange Clinic Registry, which initially enrolled almost 26 000 patients with T1D from 67 diabetes-oriented clinics in the United States, 4 showed that only~30% of patients aged ≥26 years achieved A1C <7.0%, with a lower rate (14%) for patients aged 18 to 25 years. 5 Furthermore, many patients with T1D experience significant glycaemic variability, including postprandial glucose excursions and hypoglycaemic episodes, as well as problems achieving "time in range" (TIR), defined as the percentage of time with glucose within the target range (usually >70 to ≤180 mg/dL). 6, 7 While insulin therapy is essential, many patients with T1D experience increased insulin resistance as their weight increases, requiring high doses of insulin that are often associated with adverse side effects, including hypoglycaemia, dyslipidaemia, and weight gain, which in turn increases the risk of hypertension. Therefore, clinicians have sought additional therapies that may benefit insulin-resistant patients with T1D. However, the use of adjunctive glucose-lowering therapies remains low. Among the 16 061 patients in the 2015 update to the T1D Exchange Clinic Registry, 3% of patients were taking metformin and <1% each were taking pramlintide, dipeptidyl peptidase-4 (DPP-4)
inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose co-transporter (SGLT)-2 inhibitors, or others (including thiazolidinediones and sulphonylureas). 5 Pramlintide, a soluble, injectable analogue of the β-cell hormone amylin, is approved for use with mealtime insulin in patients with T1D
or T2D 8 and has been shown to reduce postprandial hyperglycaemia and weight gain. [9] [10] [11] [12] Factors limiting its use include a high incidence of nausea, increased risk of insulin-induced postprandial hypoglycaemia, and the need for additional injections, as it cannot be mixed with insulin in the current formulation.
Off-label use of metformin as adjunctive treatment to insulin has been investigated for T1D. A meta-analysis of eight randomized controlled trials (RCTs) found that while metformin was associated with reductions in daily insulin dose, body weight, and cholesterol compared with placebo, no significant differences were found for A1C, fasting plasma glucose, or triglycerides. 13 Newer classes of glucose-lowering therapies for T2D have also been investigated for T1D. A meta-analysis of five RCTs concluded that the addition of DPP-4 inhibitors to insulin therapy showed no clear glycaemic benefit for patients with T1D vs insulin monotherapy. 14 An RCT investigating the addition of the GLP-1RA
liraglutide or placebo to insulin therapy in patients with T1D observed greater reductions in A1C, blood glucose concentrations, blood pressure (BP), and body weight with liraglutide. 15 These results suggest potential benefits of GLP-1RA treatment as adjunctive therapy, although GLP-1RAs are not currently approved for, nor in the process of seeking approval for, a T1D indication. 16, 17 SGLT-2-selective inhibitors, which reduce hyperglycaemia by increasing the elimination of glucose via the kidneys, were developed to treat patients with T2D. Accumulated evidence suggests that increased glucose elimination is predominantly explained by a marked reduction in the reabsorption of renal glucose. 18 SGLT-2 is expressed in the S1 segment of the renal proximal tubule and accounts for 80%
to 90% of filtered glucose reabsorption by the kidney, while SGLT-1 is localized to the S2/S3 segment and accounts for the remaining 10%
to 20%, although the relative contribution of SGLT-1 to glucose reabsorption appears increased under circumstances of SGLT-2 inhibition. 19, 20 SGLT-1 mediates the bulk of glucose transport in the intestine, and inhibition of SGLT-1 reduces intestinal glucose reabsorption, thereby attenuating postprandial hyperglycaemia. 18 Four SGLT-2 inhibitors are approved for the treatment of T2D in the United States-dapagliflozin, canagliflozin, empagliflozin, and ertugliflozin. [21] [22] [23] [24] In patients with T2D, SGLT-2 inhibitors have been shown to reduce A1C and fasting and postprandial glucose concentrations. [25] [26] [27] Non-glycaemic benefits include weight loss and improvement in some cardiovascular risk factors.
Because SGLT-2 inhibitors reduce hyperglycaemia through an insulin-independent, glucose-dependent mechanism, and may therefore complement insulin therapy or provide additional benefits in insulin-resistant patients, the use of SGLT-2 inhibitors as adjunctive treatment to insulin for T1D has become an area of increasing interest to investigators. Likewise, the dual SGLT-1/2 inhibitor sotagliflozin is under investigation.
We sought to consolidate the available evidence on the effects of treatment with SGLT-2 inhibitors and dual SGLT-1/2 inhibitors among patients with T1D. As such, this review summarizes the efficacy and safety data reported in prospective, double-blind RCTs of these agents as adjunctive treatment to insulin therapy in adults with T1D.
A literature search of the PubMed database was conducted on 5 July 2018 for English-language articles using the following search terms within titles and abstracts: SGLT-2 inhibitor OR sodium-glucose co- 
| Dapagliflozin
An early 2-week exploratory RCT investigated the feasibility of adding dapagliflozin to insulin among patients with T1D (n = 70).
28
Dapagliflozin 10 mg increased urinary glucose excretion by 88 g/24 h, whereas placebo was associated with a reduction in urinary glucose A subsequent post hoc analysis of this pilot study investigated the correlation between reduction in insulin dose and both glycaemic efficacy and fasting β-hydroxybutyrate, a marker of DKA. 29 The analysis identified trends for the correlation between change in total daily insulin dose and 24-hour glucose at day 7 (r = −0.264; P = .056), as well as change in total daily insulin dose and β-hydroxybutyrate at day 7 (r = −0.187; P = .133) and day 14 (r = −0.274; P = .047), with higher β-hydroxybutyrate concentrations when the insulin dose was reduced by >20%. The results suggest that insulin dose reductions should not exceed 20% to ensure optimal glycaemic efficacy of combination therapy and to reduce any potential increased risk of DKA.
The addition of dapagliflozin 10 mg to treatment with insulin plus a GLP-1RA, liraglutide, was assessed among patients with T1D
(n = 30) in a 12-week randomized, placebo-controlled study. 30 During the trial, insulin doses were titrated to a target glucose range of 70 to 160 mg/dL. Dapagliflozin significantly reduced A1C from baseline (−0.66%), whereas there was no significant change with placebo (P < .01 vs placebo). Dapagliflozin was also associated with a reduction in weight from baseline (−1.9 vs +0.7 kg with placebo [P < .05]).
No significant changes from baseline were observed in either treatment group for systolic BP (SBP), diastolic BP (DBP), or total insulin dose. The treatment groups had similar rates of hypoglycaemia. However, two patients treated with dapagliflozin developed DKA.
DEPICT-1 (Dapagliflozin Evaluation in Patients With Inade-
quately Controlled Type 1 Diabetes) was the first large, multicentre, double-blind, phase 3 RCT to investigate the efficacy and safety of dapagliflozin (5 or 10 mg) as adjunctive treatment to adjustable insulin therapy in patients with T1D (n = 833). 31 Upon initiation of dapagliflozin, it was recommended that basal and bolus insulin doses be reduced symmetrically to achieve a reduction in total daily insulin dose ≤20%, followed by titration back towards the baseline dose. After 24 weeks, both doses of dapagliflozin significantly reduced A1C and body weight from baseline compared with placebo ( Table 1) . Greater proportions of patients treated with dapagliflozin 5 or 10 mg achieved a ≥0.5% reduction in A1C with no severe hypoglycaemic events (50% and 51%, respectively, vs 25% with placebo [both P < .001]). Dapagliflozin also significantly reduced glucose exposure and glycaemic variability and increased TIR (Supporting Information, Table S1 ). In addition, dapagliflozin was associated with significant reductions in total daily insulin dose vs placebo ( Table 2) . Reductions in total insulin dose were accounted for by proportional reductions from baseline in basal and bolus insulin doses.
Results from the extension period of DEPICT-1 demonstrated sustained improvements in glycaemic control and body weight.
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After 52 weeks, both doses of dapagliflozin significantly reduced A1C from baseline vs placebo (Table 1) . Body weight reductions from baseline were maintained with dapagliflozin 5 mg, with additional weight reduction observed with dapagliflozin 10 mg (Table 1) .
Among patients with hypertension at baseline, SBP exhibited a trend towards greater reduction relative to placebo with dapagliflozin 5 mg (−1.12 mm Hg) and 10 mg (−5.38 mm Hg). Total insulin dose remained reduced at 52 weeks. Over the entire study, genital infection adverse events (AEs) occurred more frequently with dapagliflozin compared with placebo and was more common in women than men (Table 3 ). Rates of hypoglycaemia were similar T with dapagliflozin 5 mg, dapagliflozin 10 mg, and placebo (Table 3) .
T A B L E 2 Effects of SGLT-2 inhibitors and SGLT-1/2 inhibitors as an adjunct to insulin on insulin doses in RCTs
Rates of adjudicated DKA were higher with dapagliflozin 5 mg and 10 mg vs placebo (Table 4 ).
Significant reductions in A1C, body weight, and total daily insulin dose were also observed with dapagliflozin compared to placebo after 24 weeks in DEPICT-2 (n = 813; Tables 1 and 2) . 33 In DEPICT-2, it was recommended to reduce the total daily insulin dose by ≤20% upon initiation of dapagliflozin, followed by titration back towards the baseline dose. Greater proportions of patients treated with dapagliflozin 5 or 10 mg had an A1C reduction of ≥0.5% with no severe hypoglycaemic events (39.5% and 41.6%, respectively, vs 20.1% with placebo). The addition of dapagliflozin also improved glycaemic variability and increased TIR vs placebo (Table S1 ). The safety profile of dapagliflozin in DEPICT-2 was similar to that seen in DEPICT-1 (Tables 3 and 4 ).
| Empagliflozin
Various doses of empagliflozin (2.5, 10, or 25 mg) were assessed as adjunctive therapy to insulin among 75 patients with T1D in a 4-week phase 2 RCT (EASE-1). 34 The insulin regimen was kept stable for the first week of treatment and was adjusted to achieve optimal glycaemic control according to the investigator's judgment thereafter.
Daily urinary glucose excretion increased significantly from baseline with all doses of empagliflozin vs placebo after 1 week, with increases sustained at week 4 (treatment differences, +78.8 to +114.7 g/24 h [P < .001 for all]). After 4 weeks, all empagliflozin doses resulted in significantly greater reductions from baseline vs placebo in A1C and body weight ( Table 1 ). The total daily insulin dose significantly decreased with all empagliflozin doses ( treatment groups were observed for changes in SBP or DBP. EASE-1 also demonstrated improvements in glucose exposure and glycaemic variability with empagliflozin (Table S1 ). 41 AEs, including hypoglycaemia, were similar across groups, except one patient in the empagliflozin 25-mg group developed a urinary tract infection (Table 3) . 34 No DKA was reported (Table 4 ).
The effects of empagliflozin in T1D were further investigated in two RCTs of similar design (EASE-2 [52 weeks] and EASE-3
[26 weeks]; n = 1707). 35 Insulin therapy was optimized at the investigator's discretion for 6 weeks before randomization, at which time total insulin dose was reduced by 10% among patients with A1C
<8.0%. Insulin dosing adjustments continued thereafter as needed. In EASE-2 and EASE-3, empagliflozin 2.5 mg (EASE-3 only), empagliflozin 10 mg, and empagliflozin 25 mg resulted in significant reductions from baseline in A1C and body weight at week 26, which were sustained at week 52 in EASE-2 ( Table 1) . Empagliflozin was associated with increased TIR and decreased glycaemic variability in both studies (Table S1 ). Furthermore, empagliflozin significantly reduced total daily insulin usage in EASE-2 and EASE-3, with equivalent reductions in basal/bolus components ( Table 2) A pooled analysis of safety data from EASE-2 and EASE-3 showed similar rates of adjudicated severe hypoglycaemia with empagliflozin 10 mg, empagliflozin 25 mg, and placebo, with comparable rates seen in EASE-3 for empagliflozin 2.5 mg and placebo (Table 3) . 35 Empagliflozin was associated with more frequent genital infections in the pooled analysis and in EASE-3 (Table 3) . Empagliflozin 10 and 25 mg increased the risk of DKA vs placebo, while DKA rates were similar between empagliflozin 2.5 mg and placebo (Table 4) . One patient treated with empagliflozin 25 mg had a fatal DKA event related to delayed diagnosis and treatment.
| Canagliflozin
An 18-week phase 2 RCT evaluated the effects of canagliflozin vs placebo as an adjunct to insulin therapy among 351 patients with T1D. 36 To mitigate the risk of hypoglycaemia, patients with A1C ≤8.0% and >8.0% were recommended to reduce their basal insulin dose by 20%
and 10%, respectively. During treatment, patients were instructed to adjust insulin dosing according to titration algorithms. At week 18, more patients achieved the primary end point (composite goal of A1C reduction ≥0.4% with no increase in body weight) with canagliflozin 100 or 300 mg vs placebo (36.9% and 41.4% vs 14.5%, respectively [P < .001]). Consistent with this result, canagliflozin 100 and 300 mg resulted in greater placebo-subtracted reductions in A1C and body weight ( Table 1 ). The addition of canagliflozin led to reductions in total daily insulin dose and basal/bolus doses ( Table 2) .
Rates of overall hypoglycaemia were similar with canagliflozin or placebo, with a low incidence of severe hypoglycaemia (Table 3) .
However, canagliflozin was associated with an increased incidence of genital mycotic infections in women and urinary tract infections overall (Table 3) . Patients receiving canagliflozin 100 and 300 mg also had higher rates of osmotic diuresis-related AEs (7.7% and 9.4% vs 2.6%
with placebo) and volume depletion-related AEs (3.4% and 0.9% vs 0.0%). Treatment with canagliflozin 100 and 300 mg was associated with an increased risk of ketone-related AEs (5.1% and 9.4%, respectively, vs 0.0% with placebo), including DKA (Table 4) .
In a post hoc analysis of this study, patients' satisfaction with their treatment before and after treatment was assessed using the Diabe- (Table S1 ). out the trial. 37 The inTandem2 trial (n = 782) was a study of similar design to inTandem1, but undertaken at multiple sites in Europe. 38 In the inTandem3 trial, a larger proportion of patients receiving sotagliflozin 400 mg vs placebo achieved the composite goal of A1C <7.0% with no episodes of severe hypoglycaemia or DKA after 24 weeks (28.6% vs 15.2%, respectively [P < .001]). 39 Sotagliflozintreated patients had greater reductions from baseline in A1C and body weight (Table 1) , as well as reductions in SBP (treatment difference vs placebo, −3.8 mm Hg; P < .001) and DBP (−1.3 mm Hg; P < .001). Reductions in total daily insulin dose, basal insulin dose, and bolus insulin dose with sotagliflozin were also observed ( Table 2) .
| Sotagliflozin
Rates of overall hypoglycaemia were similar for patients treated with sotagliflozin or placebo, as were rates of adjudicated severe hypoglycaemia (Table 3) . However, sotagliflozin was associated with a higher rate of adjudicated DKA (Table 4) , as well as genital mycotic infections (Table 3) . Sotagliflozin was also associated with an increased incidence of diarrhoea (4.1% vs 2.3% with placebo) and volume depletion (1.9% vs 0.3%). Not reported in the publication DKA AE (classified using a pre-specified list of preferred terms) requiring hospitalization Canagliflozin 100 mg: 5/117 (4.3%) Canagliflozin 300 mg:
T A B L E 4 Rates of DKA with SGLT-2 inhibitors and SGLT-1/2 inhibitors as an adjunct to insulin in RCTs
7/117 (6.0%) Placebo: 0/117 (0.0%)
In the inTandem1 trial, the addition of sotagliflozin following insulin optimization resulted in significant reductions from baseline in A1C at week 24, which were sustained at week 52 (Table 1) . 37 In a substudy (n = 136), sotagliflozin 400 mg significantly decreased measures of glycaemic variability (Table S1 ). Both doses of sotagliflozin significantly reduced total daily insulin usage at 24 and 52 weeks, with reductions observed for basal and bolus insulin doses (Table 2) . Body weight decreased with sotagliflozin 200 mg (Table 1) , and significant reductions in BP were also observed. Placebo-adjusted reductions in SBP at week 52 were −2.8 mm Hg (P = .005) and −4.4 mm Hg (P < .001) with sotagliflozin 200 and 400 mg, respectively.
Corresponding changes in DBP were −1.4 mm Hg (P = .020) and sotagliflozin 400 mg, −0.8 [both P < .001]). The incidence of overall hypoglycaemia was similar across groups, as was adjudicated severe hypoglycaemia (Table 3) . However, sotagliflozin 200 and 400 mg were associated with increased frequencies of diarrhoea (8.4% and 10.3% vs 6.7% with placebo) and genital mycotic infections (Table 3) . Adjudicated DKA was also more common with sotagliflozin vs placebo (Table 4 ).
In the inTandem2 trial, sotagliflozin 200 and 400 mg resulted in significant reductions from baseline in A1C (Table 1) . 38 A 24-week CGM substudy of inTandem2 (n = 142) showed reductions in glycaemic variability with sotagliflozin (Table S1 ). Sotagliflozin reduced total daily insulin usage, with more prominent reductions in bolus insulin compared with basal insulin (Table 2) . Body weight decreased with both doses of sotagliflozin (Table 1) (Table 3) . Sotagliflozin 200 and 400 mg were associated with higher rates of diarrhoea (4.6% and 7.2%, respectively, vs 3.5% with placebo) and genital mycotic infections (Table 3) . Adjudicated DKA also occurred more frequently with sotagliflozin vs placebo (Table 4 ).
| DKA RISK
As summarized thus far, although the incidence of DKA was low overall, SGLT-2 inhibitors and SGLT-1/2 inhibitors were associated with an increased risk of DKA when added to insulin in patients with T1D (Table 4) . Furthermore, reports of DKA among patients with T1D treated with SGLT-2 inhibitors have been noted in case studies. [43] [44] [45] [46] [47] The prescribing information for each SGLT-2 inhibitor approved for T2D also contains a warning regarding the risk of DKA. [21] [22] [23] [24] Thus, clinicians and investigators are interested in learning more regarding the potential risk of DKA with this drug class and strategies for mitigating risk.
DKA risk was assessed in a post hoc analysis of an 18-week study of canagliflozin added to insulin in patients with T1D. 48 Patients treated with canagliflozin 100 or 300 mg had an increased incidence of any ketone-related AE (5.1% and 9.4%, respectively, vs 0.0% with placebo). Demographic and disease characteristics at baseline were similar among patients with and without a ketone-related AE, as was weight reduction at week 18. Serious AEs of DKA occurred in 4.3% and 6.0% of patients treated with canagliflozin 100 and 300 mg, respectively. Serious DKA events were concomitant with circumstances known to precipitate DKA, such as infection, reduction in insulin dose due to pump failure or poor adherence, and reduced carbohydrate intake. However, data on changes in insulin dose at the time of serious DKA events were unavailable.
In EASE-2 and EASE-3, DKA was associated with precipitating factors, including concomitant illness/infection or reduced insulin intake. 35 A subgroup analysis identified female sex and insulin pump use as important baseline risk factors for DKA. 53 while the decision on sotagliflozin is pending. Likewise, the Japanese Ministry of Health, Labour, and Welfare approved dapagliflozin as an adjunct to insulin for adults with T1D. 54 Another SGLT-2 inhibitor used for the treatment of T2D in Japan, ipragliflozin, was approved for a T1D indication in late 2018. 55 In early 2019, the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic
Drugs Advisory Committee delivered a tie vote on the use of sotagliflozin as an adjunct to insulin in patients with T1D, in whom optimal control of blood glucose levels is not achieved with insulin alone. 56, 57 A key point of consideration involved discussion of the benefits of sotagliflozin weighed against the risk of DKA, including appropriate selection of patients and whether the risk of DKA can be mitigated in the real world. However, the US FDA ultimately declined to approve sotagliflozin as an adjunct to insulin in patients with T1D. 58 Given the apparent increased risk of DKA with SGLT-2 inhibitor and SGLT-1/2 inhibitor use in T1D, it will be imperative to carefully select the patients in whom these medications will be prescribed.
There is little direct evidence to help define the ideal patient population, but the risk factors that drive DKA in patients taking these medi- Due to the associated weight loss, SGLT-2 inhibitors and SGLT-1/2 inhibitors may particularly benefit those who are overweight or obese. The majority of patients in the studies reviewed herein had a BMI in the overweight or obese ranges, representative of the general adult T1D population. 59, 60 It is unclear whether higher BMI is associated with a decreased risk of DKA in patients taking these medications, and data addressing this question would be welcome. Further research is also needed to better characterize other DKA risk factors during SGLT-2 inhibitor and SGLT-1/2 inhibitor use, and to evaluate the efficacy of specific risk mitigation strategies, including insulin dose titration and ketone testing.
| CONCLUSIONS
While insulin regimens remain the mainstay of treatment for T1D, emerging clinical data demonstrate beneficial effects of adjunctive treatment with SGLT-2 inhibitors and SGLT-1/2 inhibitors for patients with T1D. Across RCTs, the addition of these agents to insulin showed glycaemic improvements for patients with T1D, including reductions in A1C, glucose exposure, and measures of glycaemic variability, and increased TIR. Furthermore, SGLT-2 inhibitors and SGLT-1/2 inhibitors showed non-glycaemic benefits, including reductions in body weight and total daily insulin dose, and improvements in some cardiovascular risk factors. Although data were limited to a few studies, patient-reported satisfaction with treatment also improved with adjunctive treatment.
Safety data showed no increased risk of hypoglycaemia with the addition of SGLT-2 inhibitors or SGLT-1/2 inhibitors to insulin treatment. However, the benefits of adding these agents for patients with 
